CRISPR-Cas9 Knockout Screens Identify DNA Damage Response Pathways and BTK as Essential for Cisplatin Response in Diffuse Large B-Cell Lymphoma

Issa Ismail Issa(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Hulda Haraldsdóttir(Aalborg University Hospital), Soniya Dhanjal(Science for Life Laboratory), Hanne Due(Aalborg University Hospital), Vidthdyan Veeravakaran(Aalborg University Hospital), Cathrine Sylvester(Aalborg University Hospital), Rasmus Froberg Brøndum(Aarhus University), Asta Brogaard(Aalborg University Hospital), Bernhard Schmierer(Science for Life Laboratory)

Cancers

July 2, 2024

10.3390/cancers16132437

Cited by 6

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247